One day after issuing a denial (for the second time) regarding rumors of a deal for Nycomed, Takeda has confirmed its acquisition of the Swiss company for €9.6 billion (~$13.7 billion). The deal does not include Nycomed’s US dermatology business, which will be spun off.
Yasuchika Hasegawa, President & CEO of Takeda, said: “Takeda is committed to transforming our organization through the acquisition of Nycomed. Nycomed enables Takeda to maximize the value of our portfolio and gives us an immediate strong presence in the high-growth emerging markets while doubling Takeda’s European sales. Nycomed’s strength in a geographically wide range of markets and its diverse talent base will be a strong driver to helping us realize our important mission of striving toward better health for patients worldwide through leading innovation in medicine.”
Takeda particularly mentions Nycomed’s Daxas roflumilast for the treatment of COPD as a major asset. Nycomed also has a ciclesonide MDI and a ciclesonide nasal spray.
Read the Takeda press release.
